Beam Therapeutics Inc.BEAMNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank38
5Y CAGR-33.6%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-33.6%/yr
Long-term compound
Percentile
P38
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 11.44% |
| 2024 | -15.96% |
| 2023 | 40.37% |
| 2022 | -19.50% |
| 2021 | 275.16% |
| 2020 | 88.91% |
| 2019 | 61.25% |
| 2018 | 478.14% |
| 2017 | 0.00% |